Purpose of the study: * to assess the efficacy of Subetta in the treatment of impaired glucose tolerance * to assess the safety of Subetta in the treatment of impaired glucose tolerance.
Design: a multicenter, double-blind, placebo-controlled, parallel-group randomized trial. The study will enroll outpatients adults aged 18 to 70 years with impaired glucose tolerance (IGT) who did not receive glucose-lowering agents previously. Persons with pre-diabetes, obesity (especially with visceral or abdominal obesity), dyslipidemia (with high triglycerides and/or low-density lipoproteins), hypertension, diabetes in first-degree relatives will be considered as potential candidates to participate in the study. After the patient's information sheet and the form of informed consent for participation in the study are signed on the screening (visit 0; day from -7 to 0), complaints and history are collected, registration of concomitant conditions and diseases, objective examination, calculation of body mass index (BMI), oral glucose tolerance test (OGTT), fasting blood glucose. Furthermore, blood samples (for testing HbA1c, chemistry and hematology, HLA genotyping) and urine sample will be collected; concomitant therapy will be recorded, diet and physical activity recommendations will be given. All women of childbearing potential will be administered pregnancy tests. If eligibility criteria are met and there are no non-inclusion criteria on Visit 1 (Day 1), the patient is randomized to one of two groups: the Subetta group (patients will take 2 tablets twice a day for 12 weeks) or placebo group (patients will take a placebo according to the scheme of Subetta for 12 weeks). In the course of the study, two more visits in 4 (Visit 2) and 12 (Visit 3) weeks are planned, during these weeks complaints are recorded, a patient's examination is recorded, therapy compliance and safety are assessed. On Visit 3 OGTT, fasting blood glucose, blood samples (for HbA1c, chemistry and hematology) and urinalysis will be performed. The duration of observation period shall be up to 13 weeks. During the study the treatment for underlying conditions will be allowed with the exception of the drugs indicated in the section "Prohibited concomitant therapy".
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
538
Change 2-hour Plasma Glucose (During Oral Glucose Tolerance Test).
Based on medical records. For oral glucose tolerance test, the subject is given 75 g of oral glucose and blood sample is taken 2 hours later. All analysis will be done in a central laboratory.
Time frame: At baseline and after 12 weeks of treatment.
Percentage of Patients With 2-hour Plasma Glucose <7.8 mmol / L.
Based on medical records.
Time frame: After 12 weeks of treatment.
Change in Fasting Plasma Glucose.
Based on medical records. Fasting plasma glucose is measured after fasting or not eating anything for at least 8 hours.
Time frame: At baseline and after 12 weeks of treatment.
Change in HbA1c
Based on medical records. HbA1c is determined by the method certified in accordance with National Glycohemoglobin Standardization Program and standardized in compliance with the reference values adopted in the Diabetes Control and Complications Trial.
Time frame: At baseline and after 12 weeks of treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arkhangelsk Regional Clinical Hospital
Arkhangelsk, Russia
Belgorod State National Research University
Belgorod, Russia
Kirov Clinical Hospital № 7 named. V.I. Yurlova
Kirov, Russia
Kuban State Medical University
Krasnodar, Russia
Regional Clinical Hospital #1 named after Professor Ochapovsky
Krasnodar, Russia
Clinic of Professor Gorbakov
Krasnogorsk, Russia
Krasnogorsk city hospital №1
Krasnogorsk, Russia
City Clinical Hospital named after F.I. Inozemtseva Department of Health of Moscow
Moscow, Russia
City Clinical Hospital named after V.P. Demikhova
Moscow, Russia
Moscow Clinical Scientific and Practical Center of the Moscow City Health Department
Moscow, Russia
...and 34 more locations